JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1998; 32:1648-1656
© 1998 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ruotolo, G.
Right arrow Articles by Hamsten, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruotolo, G.
Right arrow Articles by Hamsten, A.

Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)

Giacomo Ruotolo, MD, PhD*, Carl-G.öran Ericsson, MD, PhD||, Cristina Tettamanti, BSc*, Fredrik Karpe, MD, PhD* {dagger}, Lars Grip, MD, PhD{ddagger}, Bertil Svane, MD, PhD§, Jan Nilsson, MD, PhD* {dagger}, Ulf de Faire, MD, PhD{dagger} and Anders Hamsten, MD, PhD* {dagger}

* Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Hospital, Stockholm, Sweden
{dagger} Department of Emergency and Cardiovascular Medicine, Karolinska Hospital, Stockholm, Sweden
{ddagger} Department of Cardiology, Karolinska Hospital, Stockholm, Sweden
§ Department of Thoracic Radiology, Karolinska Hospital, Stockholm, Sweden
|| Division of Cardiology, Department of Medicine, Danderyd Hospital, Stockholm, Sweden



View larger version (14K):

[in a new window]
  		Figure 1 LDL peak particle size (upper panel) and percentage small LDL (<22.8 nm) of total LDL (lower panel) in the two study groups (circles, placebo; squares, bezafibrate). LDL peak particle size and percentage small LDL were measured at baseline and at 2 and 5 years. Values are mean ± SD. Data were analyzed by two-way repeated measures ANOVA (LDL peak particle size: group p = 0.27, time p = 0.0003, interaction p = 0.001; percentage small LDL: group p = 0.76, time p < 0.0001, interaction p < 0.0001). *p < 0.05, ***p < 0.001 between {Delta} values of the two study groups.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1998 by the American College of Cardiology Foundation.